vg2025
Biologicalexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 23, 2022 (NCT05477849)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07262164 | Phase 1 | Jan 31, 2026 | Shanghai Virogin Biotech Co., Ltd. |
| NCT06365918 | Phase 1 | Sep 30, 2024 | University of Texas at Houston |
| NCT05266612 | Phase 1 | Nov 1, 2022 | Shanghai Virogin Biotech Co., Ltd. |
| NCT05477849 | Phase 1 | Aug 23, 2022 | Shanghai Virogin Biotech Co., Ltd., Zhejiang University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Virogin Biotech Co., Ltd. | For profit | 3 | 3 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1